A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function

por Brod, M, Wolden, M, Christensen, T, Bushnell, D M
Publicado 2013

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia

por Heller, S., Mathieu, C., Kapur, R., Wolden, M. L., Zinman, B.
Publicado 2015

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials

por Freemantle, N, Evans, M, Christensen, T, Wolden, M L, Bjorner, J B
Publicado 2013

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase...

por Freemantle, N, Meneghini, L, Christensen, T, Wolden, M L, Jendle, J, Ratner, R
Publicado 2013

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management

por Kolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., Bjorner, J. B.
Publicado 2016

Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, r...

por Knudsen, S. T., Lapolla, A., Schultes, B., Tentolouris, N., Catarig, A.‐M., Wolden, M. L., Siegmund, T.
Publicado 2019

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes

por Rodbard, H W, Cariou, B, Zinman, B, Handelsman, Y, Wolden, M L, Rana, A, Mathieu, C
Publicado 2014